Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Larry G. who wrote (712)	6/18/2000 6:55:00 PM
From: Sean Janzen	Read Replies (2) \| Respond to of 792

Larry, The following link is to Harbor-UCLA Research and Education Institute: rei.edu I know nothing of this institution but suspect that any products to reach human clinical trials from this collaboration will come years from now. At that time, MBI will be an established company. What I find far more interesting it this link to the FDA. fda.gov click on "antibiotics" then scroll up to the heading Section 112 - Fast Track Drug Development and click on "Guidance". Read the article: Guidance for Industry - Fast Track Drug Development Programs - Designation, Development, and Application Review. I suspect that MBI's 2 other products in Human Clinical Trials, MBI 594AN and MBI 853NL, will qualify for fast track approval. MBI could have 3 products in or qualified for Phase III within 6-12 months, just my opinion. Sean p.s. I still believe the Recap web site is accurate in suggesting MBI 226 is undergoing Human Clinical Trials for the secondary indication severe acne. MBI has not responded to my email on this question.

To: Larry G. who wrote (712)	7/3/2000 11:00:22 PM
From: Sean Janzen	Read Replies (3) \| Respond to of 792

Larry, I have had a chance to search the Harbor UCLA Research and Education Institute web site. Here are a few links that should give investors insight into that institution. I get the impression that the drugs developed from this relationship will be candidates for fast track approval. Harbor-UCLA Medical Center Division of Infectious Diseases Faculty Profiles: rei.edu Selected ongoing research projects in the Division of Infectious Diseases: rei.edu Two REI Researchers Share 1999 Weitzman Award Two researchers from the Harbor-UCLA Research and Education Institute (REI) in Torrance have been named the winners of the 1999 Weitzman Award. The award, presented annually by the Harbor-UCLA Medical Center Faculty Society, recognizes outstanding young investigators’ meritorious clinical or basic research in the biomedical sciences. Dr. Yeaman is a graduate of the University of New Mexico. His research focuses on the role of platelets and platelet peptides in defending against infectious diseases, and he has developed novel peptide antibiotics which are proving effective against antibiotic-resistant pathogens. He is the first or senior author of more than 35 peer-reviewed publications, has coauthored five book chapters and has six additional manuscripts submitted for publication. rei.edu